T. King
Pulmonary and Respiratory Medicine · American Journal of Respiratory and Critical Care Medicine · 2001–2014
A researcher in the Science corpus: 15 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 53 citations into it; #238 of 770 by trust here, #54 by citations
- Physiology — 12 citations into it; #1,426 of 2,276 by trust here, #690 by citations
Whom T. King trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts T. King overall
Papers from T. King's perspective
Ordered by how strongly the researchers T. King trusts endorse each paper. Same corpus, a different order for every researcher.
- A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis (New England Journal of Medicine)
- Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. (Chest)
- Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. (American Journal of Respiratory and Critical Care Medicine)
- Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? (American Journal of Respiratory and Critical Care Medicine)
- The measurement of observer agreement for categorical data.
- Incidence and prevalence of idiopathic pulmonary fibrosis. (American Journal of Respiratory and Critical Care Medicine)
- Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity (European Respiratory Journal)
- Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours (Journal of Thoracic Oncology)
- Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction (Epidemiology)
Their papers
- A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. (2014) — 2,093 citations
- An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. (2013) — 3,543 citations
- A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis (2012) — 1,181 citations
- Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis (2012) — 1,386 citations
- Clinical course and prediction of survival in idiopathic pulmonary fibrosis. (2011) — 1,495 citations
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. (2011) — 2,026 citations
- BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. (2011) — 659 citations
- The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis (2005) — 596 citations
- A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. (2004) — 608 citations
- Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? (2004) — 627 citations
- Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. (2003) — 744 citations
- American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias (2002) — 3,677 citations
- Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. (2001) — 882 citations
- Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy (2001) — 1,825 citations
- Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. (2001) — 635 citations